Health Encyclopedia

 

Document Search by P08128



Hereditary Breast Ovarian Cancer Syndrome (BRCA1/BRCA2)Síndrome hereditario de cáncer del seno y de ovario (BRCA1 / BRCA2)

What is hereditary breast ovarian cancer (HBOC) syndrome?

HBOC syndrome is characterized by the following features in a family:

  • An early age onset of breast cancer (often before age 50)

  • Family history of both breast and ovarian cancer

  • Increased chance of bilateral cancers (cancer that develops in both breasts, or both ovaries, independently) or an individual with both breast and ovarian cancer

  • An autosomal dominant pattern of inheritance (transmission through either the mother or father’s side of the family)

  • An increased incidence of tumors of other specific organs, such as the prostate

Other factors that increase the chance that a family has the hereditary breast ovarian cancer syndrome include:

  • Family history of male breast cancer

  • Ashkenazi Jewish ancestry

What are the BRCA1 & BRCA2 genes?

In 1990, DNA linkage studies on large families with the above characteristics identified the first gene associated with breast cancer. Scientists named this gene breast cancer 1 or BRCA1 (pronounced brak-uh). BRCA1 is located on chromosome 17. Mutations in the gene are transmitted in an autosomal dominant pattern in a family.

Since it was clear that not all breast cancer families were linked to BRCA1, studies continued and in 1994, scientists discovered another gene (similar to BRCA1) and named it BRCA2. BRCA2 is located on chromosome 13. Mutations in this gene are also transmitted in an autosomal dominant pattern in a family.

Both BRCA1 and BRCA2 are tumor suppressor genes that usually have the job of controlling cell growth and cell death. They also are important for DNA repair. Everyone has 2 BRCA1 (1 on each chromosome #17) and 2 BRCA2 genes (1 on each chromosome #13). When a person has 1 altered or mutated copy of either the BRCA1 or BRCA2 gene, it can lead to deficient repair of DNA damage and the accumulation of mutations. Some of these acquired mutations can lead to a tumor formation, increasing the person's risk for various breast, ovarian, prostate, laryngeal, stomach cancer, and melanoma cancers.

However, mutations in these genes are rare in the general population. Estimates are that they account for no more than 5% to 10% of all breast and ovarian cancer cases. Still, the most common cause of hereditary breast cancer is an inherited mutation in the BRCA1 and BRCA2 genes. The risk may be as high as 80% for members of some families with BRCA mutations.

Both copies of a tumor suppressor gene must be altered or mutated before a person will develop cancer. In HBOC, the first mutation is inherited from either the mother or father and is present in all cells of the body. This is called a germline mutation. Whether a person who has a germline mutation will develop cancer and where the cancer(s) will develop depends on where (which cell type) the second mutation occurs. For example, if the second mutation is in the ovary, then ovarian cancer may develop. If it is in the breast, breast cancer may develop. The process of tumor development actually requires mutations in multiple growth control genes. Loss of both copies of BRCA1 or BRCA2 is just the first step in the process. What causes these additional mutations to be acquired is unknown. Possible causes include chemical, physical, or biological environmental exposures, or chance errors in cell replication.

Some individuals who have inherited a germline BRCA1 or BRCA2 mutation never develop cancer because they never get the second mutation necessary to knock out the function of the gene and start the process of tumor formation. This can make the cancer appear to skip generations in a family, when, in reality, the mutation is present. People with a mutation, regardless of whether they develop cancer, however, have a 50/50 chance to pass the mutation on to the next generation.

It is also important to remember that the BRCA1 and BRCA2 genes are not located on the sex chromosomes. So, mutations can be inherited from the mother or the father’s side of the family.

What is a founder's effect?

One final point that needs to be understood about BRCA1 and BRCA2 is a concept known as the founder effect. The majority of people who have a BRCA1 or BRCA2 mutation have a unique mutation — 1 that is specific to them and their family. To date, hundreds of unique mutations have been identified in both BRCA1 and BRCA2. However, there are a few exceptions. For instance, specific recurring mutations have been found in people of Ashkenazi Jewish descent, and people from the Netherlands, Iceland, and Sweden. Mutations recur in these groups because of a founder’s effect. Founders are a small group of people who, due to geographic or religious isolation, interbreed. When a small group of people interbreeds over generations, specific rare mutations can recur and become more common in the population. This is called a founder’s effect.

The present day Ashkenazi Jewish population arose from a small group of founders, of whom 1 or more must have carried specific mutations in the BRCA1 and BRCA2 genes. In particular, there are 3 mutations (2 in BRCA1 and 1 in BRCA2) that account for the majority of the BRCA mutations seen in people of Ashkenazi Jewish ancestry. This information has practical meaning when it comes to genetic testing because some laboratories now offer “ethnic-specific” mutation panels. Rather than searching through the entire gene every time a person is tested, in some cases, laboratories can instead first look for specific mutations based on a person’s ethnic background. The founder effect is also important in Ashkenazi Jewish people because it has led to an increased occurrence of BRCA mutations in this population. In the general population, it is estimated that 1 in 800 people has a mutation in BRCA1 or BRCA2. In contrast, 1 in 40 Ashkenazi people has 1 of the recurring mutations. This increased occurrence has implications in terms of assessing the significance of a family history of breast and ovarian cancer in Ashkenazi versus non-Ashkenazi people.

 
Related Items
Wellness Library
  Solving the Breast Cancer Puzzle
  Reducing Your Risk for Breast Cancer
  Certain Factors Help Predict Invasive Breast Cancer
  Hope on the Horizon for Breast Cancer
  Stay Healthy After Breast Cancer
Content Type 167
  BRCA
  CA 15-3
  CA 27-29
  Immunohistochemical Test for Estrogen and Progesterone Receptors
Cancer Source
  Sex and Cancer: Questions for Your Doctor
  Breast Cancer—Understanding Genetic Testing
  The Soy and Breast Cancer Controversy: Cause for Concern?
  The 'Chemobrain' Phenomenon in Breast Cancer
  MRIs for Breast Cancer Screening—Who Needs Them?
  Hormonal Therapy: Managing Side Effects in Women
  If You Are Having Hormonal Therapy
  What Is Breast Cancer?
  What to Know About Your Treatment Choices for Breast Cancer
  Ductal Carcinoma
  Statistics About Breast Cancer
  Can I Get Checked for Breast Cancer Before I Have Symptoms?
  What Can I Do if I Am at Risk for Breast Cancer?
  What Are the Symptoms of Breast Cancer?
  How Does My Doctor Know I Have Breast Cancer?
  Tests That Help Evaluate the Traits of Your Breast Cancer
  Understanding Your Grade and Stage of Breast Cancer
  What to Know About Surgery for Breast Cancer
  Breast Cancer: What Happens After Reconstructive Surgery
  Goal of Chemotherapy for Breast Cancer
  Do What You Can to Ease Side Effects of Treatment and Symptoms for Breast Cancer
  Finding Out You Have Breast Cancer
  What to Know About Combination Therapy for Breast Cancer
  How You Get Radiation for Breast Cancer
  What You Need to Know About Hormone Therapy for Breast Cancer
  Tips for Feeling Your Best During Treatment for Breast Cancer
  Taking Care of Your Incision After Breast Surgery
  How Your Doctor Uses Biopsies to Make Your Diagnosis of Breast Cancer
  Understanding Your Type of Breast Cancer
  What to Know About Inflammatory Breast Cancer (IBC)
  Can I Survive Breast Cancer? What Is My Prognosis?
  Am I at Risk for Breast Cancer?
  Myths About What Causes Breast Cancer
  Questions to Ask About Treatment for Breast Cancer
  What to Expect After Surgery for Breast Cancer
  What Happens During Radiation Therapy for Breast Cancer
  What to Expect After Radiation Treatment for Breast Cancer
  What Happens During Chemotherapy for Breast Cancer
  Making the Decision to Have Hormone Therapy for Breast Cancer
  What Happens During Hormone Therapy for Breast Cancer
  Ovarian Ablation as Hormone Therapy for Breast Cancer
  What to Expect After Taking Hormone Therapy Drugs for Breast Cancer
  What to Know About Targeted Therapy for Breast Cancer
  What Happens During Targeted Therapy for Breast Cancer
  Making the Decision to Have Breast Reconstruction After a Mastectomy for Breast Cancer
  When Breast Cancer Spreads to the Bones
  Exercising After Breast Cancer: Moving Toward Health
  Aromatase Inhibitors for Breast Cancer
Cancer FAQs
  Breast Cancer FAQ
NCI Patient Summary
  Breast Cancer Treatment and Pregnancy (PDQ®)
Quizzes
  Breast Cancer Quiz
MRAs
  Breast Cancer Risk Assessment
Adult Diseases and Conditions
  Breast Cancer Prevention Trial (BCPT)
  Chemotherapy for Breast Cancer Treatment
  About Clinical Trials: Information from the National Cancer Institute
  How Is Breast Cancer Diagnosed?
  General Information About Breast Cancer
  Other Treatments for Breast Cancer
  National Surgical Adjuvant Breast and Bowel Project (NSABP)
  Post-Mastectomy
  Radiation Therapy for Breast Cancer Treatment
  Risk Factors for Breast Cancer
  Signs and Symptoms of Breast Cancer
  Stages of Breast Cancer
  Study of Tamoxifen and Raloxifene (STAR)
  Breast Cancer Statistics
  About Taxol
  Breast Health: Three-Step Plan for Preventive Care
  Treatments for Breast Cancer
  Genetics of Breast Cancer
  Breast Cancer Overview
Newsletters
  Should You Consider Preventive Drugs for Breast Cancer?
  Should You Be Tested for the Breast Cancer Gene?
Test and Procedures
  Breast Biopsy